3Eschbach J W, Egrie J C, Downing M R, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Resuits of a combined phase Ⅰ and Ⅱ clinical trial[J]. N Engl J Med, 1987,316(2) :73-78.
4Abels R I. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer[ J ]. Semin Oncol, 1992,19(3 suppl 8) :29-35.
5Steve E, Joan E, Jeff B, et al. Control of rHuEPO biological activity: The role of carbohydrate[J]. Exp Hematol,200d,32(12) : 1146-1155.
6Egrie J C, Browne J K. Development and characterization of novel erythroiesis stimulating protein(NESP) [ J ]. Br J Cancer, 2001,84 ( suppl 1):3-10.
7Eschbach J W, Egrie J C, Downing M R, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin[ J]. N Engl J Med, 1987,316(2) :73-78.
8Abels R I. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer[J]. Semin Oncol, 1992,19(3 suppl 8) :29-35.
9Louise C W, Gregg T, Patricia M. The important of N-and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin[ J]. Blood,1991,77(12) :2624-2632.
10Steve E, Joan E, Jeff B, et al. Control of rHuEPO biological activity : The role of carbohydrate[ J]. Exp Hematol,2004,32(12) : 1146-1155.
